Possible therapeutic approaches to target the immunosuppressive activity of MDSCs include the inhibition of COX2 to reduce MDSCs recruitment and reduce Arg I expression (26) and blocking CSF-1, CXCL2, or CXCL12 to inhibit trafficking of MDSCs to the tumor (20). Here, CXCL12 is linked to neoplasm.